XBiotech Inc.
XBIT · XNASCIK 1626878fmd_1PBV1CAX6PSRAJ66XHHF9ZP5SQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 53 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 44 | 18 | 4 | 0 | – | – |
| Cost of revenue | – | – | 0 | 0 | 35 | 6 | 1 | 0 | – | – |
| Gross profit | – | – | 0 | 0 | 9 | 13 | 3 | 0 | – | – |
| Research and development | 42 | 26 | 16 | 24 | 10 | 28 | 32 | 33 | 38 | 47 |
| Total operating expenses | 53 | 34 | 21 | 31 | 28 | 38 | 38 | 38 | 42 | – |
| Operating income | (53) | (34) | (21) | (31) | (18) | (25) | (34) | (38) | (42) | (56) |
| Other non-operating income (expense) | 0 | 1 | (0) | 750 | 5 | (0) | 1 | 13 | 4 | 10 |
| Income before taxes | (53) | (33) | (21) | 718 | (13) | (25) | (34) | (24) | (39) | (45) |
| Income tax expense | 0 | 0 | 0 | 50 | (2) | (8) | (1) | 0 | (0) | 0 |
| Net income from continuing operations | (53) | (33) | (21) | 669 | (11) | (17) | (33) | (25) | (39) | (46) |
| Net income | (53) | (33) | (21) | 669 | (11) | (17) | (33) | (25) | (39) | (46) |